Copertina

Quantitative Prediction of Human Pharmacokinetics for Fc‐Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kenta Haraya, Taichi Kuramochi
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Clinical and Translational Science
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
di: Hui‐Ning Li, et al.
Pubblicazione: (2025)

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker
di: Tiancheng Luo, et al.
Pubblicazione: (2025)

Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies
di: Wenhui Zhang, et al.
Pubblicazione: (2025)

Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV ‐2 Variants
di: Qianwen Wang, et al.
Pubblicazione: (2025)

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities
di: Nai Lee, et al.
Pubblicazione: (2025)

Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121)
di: Richard Fitch, et al.
Pubblicazione: (2025)

The Dorsal Forearm as a Novel Target for Intramuscular Injections: Clinical Pharmacokinetic Results With Naloxone
di: Thomas F. Krol, et al.
Pubblicazione: (2025)

When Selectivity Increases Uncertainty: Context‐Dependent Pharmacology in Antibody Drug Development
di: Xiaozhi Liao, et al.
Pubblicazione: (2026)

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis
di: Rasmus Hansen Henninger, et al.
Pubblicazione: (2026)

Primary SARS‐CoV‐2 infection in children and adults results in similar Fc‐mediated antibody effector function patterns
di: Anne T Gelderloos, et al.
Pubblicazione: (2024)

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
di: Shan Pan, et al.
Pubblicazione: (2026)

Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients
di: Anitha Saravanakumar, et al.
Pubblicazione: (2026)

Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis
di: Cindy X. Zhang, et al.
Pubblicazione: (2025)

Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug–Drug Interactions After Posaconazole Discontinuation
di: Rebecca E. Wrishko, et al.
Pubblicazione: (2026)

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers
di: Bhagwat Prasad
Pubblicazione: (2026)

Predicting the Pharmacokinetics of T‐Cell Engagers as a Function of Target‐Mediated Drug Disposition
di: Mark Penney, et al.
Pubblicazione: (2025)

First‐In‐Human Safety, Tolerability, and Pharmacokinetics of PPI‐1011, a Synthetic Plasmalogen Precursor
di: Tara Smith, et al.
Pubblicazione: (2025)

Pharmacokinetics as a Biomarker
di: John A. Wagner, et al.
Pubblicazione: (2026)

Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics
di: Hui Yu, et al.
Pubblicazione: (2025)

Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis
di: Atul Rawal, et al.
Pubblicazione: (2025)

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
di: Virginia D. Schmith, et al.
Pubblicazione: (2026)

First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
di: Tomoki Kojima, et al.
Pubblicazione: (2026)

Predicting Pharmacokinetics in Rats Using Machine Learning: A Comparative Study Between Empirical, Compartmental, and PBPK ‐Based Approaches
di: Moritz Walter, et al.
Pubblicazione: (2025)

Pharmacokinetic‐Pharmacodynamic Model of Paclitaxel‐Induced Peripheral Neuropathy
di: Yuchen Sun, et al.
Pubblicazione: (2025)

Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
di: Jumar Etkins, et al.
Pubblicazione: (2025)

Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
di: Olivier Schueller, et al.
Pubblicazione: (2025)

Correction to “Genotype‐Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers”
Pubblicazione: (2026)

Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma
di: Cheryl Li, et al.
Pubblicazione: (2025)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
di: Ngoc Hoa Truong, et al.
Pubblicazione: (2025)

Real‐World Impact of Amiodarone on Apixaban Population Pharmacokinetics in Hospitalized Patients
di: Samantha Kolowrat, et al.
Pubblicazione: (2025)

Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome
di: Kevin Lam, et al.
Pubblicazione: (2025)

Hemodynamic and Pharmacokinetic Interactions of TPN171 with Alcohol in Healthy Male Subjects
di: Jie Cheng, et al.
Pubblicazione: (2025)

Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo‐Controlled, Parallel Group, First‐In‐Human Study in Healthy Male Participants
di: Marella C. E. van Ruissen, et al.
Pubblicazione: (2025)

Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers
di: Pablo E. Pergola, et al.
Pubblicazione: (2024)

Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin
di: Sayanit Tipnoppanon, et al.
Pubblicazione: (2026)

Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia
di: Hengbang Wang, et al.
Pubblicazione: (2026)

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
di: Huijun Chen, et al.
Pubblicazione: (2024)

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients
di: Kun Wang, et al.
Pubblicazione: (2025)

Challenges in Extrapolating Healthy Volunteer Pharmacokinetics to Oncology Populations: Advocating for a Holistic Perspective
di: Yan Ji, et al.
Pubblicazione: (2025)

Population Pharmacokinetics and Exposure–Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer
di: Carlos Fernandez Teruel, et al.
Pubblicazione: (2025)